CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← BeyondSpring Inc. (BYSI) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

BeyondSpring Inc. (BYSI)

Pharmaceutical Preparations · market cap $31M · as of 2026-10-27

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
None scheduled
Pipeline
7
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
BeyondSpring Inc. (BYSI) is a micro-cap pharmaceutical company (market cap ~$19M, ~41.1M shares, price ~$0.46). Its lead asset is plinabulin, listed at Phase 3 for chemotherapy-induced neutropenia (CIN), with other programs in NSCLC listed as Phase 2/3. The setup is dominated by balance-sheet pressure: $2.7M of cash, a 5.2-month runway, and a completed offering on 2026-09-29.
The catalyst path

No upcoming catalysts in our calendar.

Pipeline
AssetPhaseIndication
Docetaxel + Plinabulin (DP)Phase 3Non-Small Cell Lung Cancer
PlinabulinPhase 3Chemotherapy-induced Neutropenia
PegfilgrastimPhase 3Chemotherapy-induced Neutropenia
Nitric OxidePhase 3Bronchiolitis
Docetaxel (D)Phase 3Non-Small Cell Lung Cancer
Docetaxel, doxorubicin, and cyclophosphamide (TAC)Phase 2Chemotherapy-induced Neutropenia
Pembrolizumab in Combination with Plinabulin and DocetaxelPhase 2Non Small Cell Lung Cancer Metastatic
Price & technical context
3-month
-15.5%
6-month
-55.9%
12-month
-71.7%
52-wk range
$0.43–$2.35
vs 50-day MA
-8.5%
vs 200-day MA
-50.9%
Realized vol
111.4%
Max drawdown
-87.4%

Daily closes through 2026-11-13. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for BYSI (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 7 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.